# EDGAR Filing Document

**Accession Number:** 0001840877
**File Stem:** 0001213900-26-013894
**Filing Date:** 2026-2
**Character Count:** 64123
**Document Hash:** 6d33e370f5e305f3ce050843c7973c66
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-013894.hdr.sgml**: 20260210

**ACCESSION NUMBER**: 0001213900-26-013894

**CONFORMED SUBMISSION TYPE**: S-1/A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260210

**DATE AS OF CHANGE**: 20260209

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Envoy Medical, Inc.
- **CENTRAL INDEX KEY:** 0001840877
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 861369123
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1/A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-292260
- **FILM NUMBER:** 26613300

**BUSINESS ADDRESS:**
- **STREET 1:** 4875 WHITE BEAR PARKWAY
- **CITY:** WHITE BEAR LAKE
- **STATE:** MN
- **ZIP:** 55110
- **BUSINESS PHONE:** 651-361-8000

**MAIL ADDRESS:**
- **STREET 1:** 4875 WHITE BEAR PARKWAY
- **CITY:** WHITE BEAR LAKE
- **STATE:** MN
- **ZIP:** 55110

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Anzu Special Acquisition Corp I
- **DATE OF NAME CHANGE:** 20210115

**As filed with the U.S. Securities and Exchange Commission on February 9, 2026**

**Registration No. 333-292260**

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**

**AMENDMENT NO. 2**

**TO**

**FORM S-1<br> REGISTRATION STATEMENT<br> UNDER<br> THE SECURITIES ACT OF 1933**

**Envoy Medical, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **3842** | **86-1369123** |
| (State or other jurisdiction of <br> incorporation or organization) | (Primary Standard Industrial <br> Classification Code Number) | (IRS Employer <br> Identification Number) |

---

**4875 White Bear Parkway**

**White Bear Lake, MN 55110**

**Tel: (877) 900-3277**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**Brent T. Lucas**

**Chief Executive Officer**

**Envoy Medical, Inc.**

**4875 White Bear Parkway**

**White Bear Lake, MN 55110**

**Tel: (877) 900-3277<br> (Name, address, including zip code, and telephone number, including area code, of agent for service)**

**With copies to:**

---

| | |
|:---|:---|
| **Andrew M Nick, Esq**. | **Steven M. Skolnick, Esq.** |
| **Fredrikson & Byron, P.A.** | **Lowenstein Sandler LLP** |
| **60 South Sixth Street; Suite 1500** | **1251 Avenue of the Americas** |
| **Minneapolis, MN 55402** | **New York, New York 10020** |
| **(612) 492-7000** | **(212) 262-6700** |

---

Approximate date of commencement of proposed sale to the public: From time to time after this Registration Statement becomes effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 (the "Securities Act") check the following box: ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.**

**EXPLANATORY NOTE**

Envoy Medical, Inc. is filing this Amendment No. 2 to its Registration Statement on Form S-1, as amended (File No. 333-292260), as an exhibits-only filing. Accordingly, this amendment consists only of the facing page, this explanatory note, Item 16(a) of Part II of the Registration Statement, the signature page to the Registration Statement and the filed exhibits. The remainder of the Registration Statement is unchanged and has been omitted.

**PART II** 

**INFORMATION NOT REQUIRED IN PROSPECTUS**

**Item 16. Exhibits.**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| <br>**Exhibit <br> Number** | <br>**Description** | **Schedule/<br> Form** | **File No.** | **Exhibit** | **Filing Date** |
| 3.1 | [Second Amended and Restated Certificate of Incorporation of the Company.](http://www.sec.gov/Archives/edgar/data/1840877/000101376223002246/ea186352ex3-1_envoy.htm) | 8-K | 001-40133 | 3.1 | October 5, 2023 |
| 3.2 | [Amended and Restated Bylaws of the Company.](http://www.sec.gov/Archives/edgar/data/1840877/000101376223002246/ea186352ex3-2_envoy.htm) | 8-K | 001-40133 | 3.2 | October 5, 2023 |
| 3.3 | [Certificate of Designation of Series A Preferred Stock of the Company.](http://www.sec.gov/Archives/edgar/data/1840877/000101376223002246/ea186352ex3-3_envoy.htm) | 8-K | 001-40133 | 3.3 | October 5, 2023 |
| 4.1 | [Warrant Agreement, dated March 1, 2021, between Anzu Special Acquisition Corp I and Equiniti Trust Company, LLC (formerly known as American Stock Transfer & Trust Company, LLC), as Warrant Agent.](http://www.sec.gov/Archives/edgar/data/1840877/000110465921032172/tm213438d11_ex10-1.htm) | 8-K | 001-40133 | 10.1 | March 4, 2021 |
| 4.2 | [Form of Shortfall Warrant.](http://www.sec.gov/Archives/edgar/data/1840877/000121390024014271/fs12024a1ex4-2_envoy.htm) | S-1/A | 333-276590 | 4.2 | February 15, 2024 |
| 4.3 | [Description of Securities.](http://www.sec.gov/Archives/edgar/data/1840877/000121390024028894/ea020296601ex4-3_envoy.htm) | 10-K | 001-40133 | 4.3 | April 1, 2024 |
| 4.4 | [Form of Private Warrant.](http://www.sec.gov/Archives/edgar/data/1840877/000101376225004299/ea023532001ex4-4_envoy.htm) | 10-K | 001-40133 | 4.4 | March 31, 2025 |
| 4.5 | [Form of September Private Placement Warrant](http://www.sec.gov/Archives/edgar/data/1840877/000121390025090373/ea025837101ex4-1_envoy.htm) | 8-K | 001-40133 | 4.1 | September 23, 2025 |
| 4.6 | [Form of September Placement Agent Warrant](http://www.sec.gov/Archives/edgar/data/1840877/000121390025090373/ea025837101ex4-2_envoy.htm) | 8-K | 001-40133 | 4.2 | September 23, 2025 |
| 4.7 | [Form of October Private Placement Warrant](http://www.sec.gov/Archives/edgar/data/1840877/000121390025097600/ea026075301ex4-1_envoy.htm) | 8-K | 001-40133 | 4.1 | October 9, 2025 |
| 4.8 | [Form of October Placement Agent Warrant](http://www.sec.gov/Archives/edgar/data/1840877/000121390025097600/ea026075301ex4-2_envoy.htm) | 8-K | 001-40133 | 4.2 | October 9, 2025 |
| 4.9 (\*\*) | [Form of Pre-Funded Warrant to be issued in this offering](https://www.sec.gov/Archives/edgar/data/1840877/000121390026013098/ea027581701ex4-9_envoy.htm) | S-1 | 333-292260 | 4.9 | February 6, 2026 |
| 4.10 (\*\*) | [Form of Series A-1 Warrant to be issued in this offering](https://www.sec.gov/Archives/edgar/data/1840877/000121390026013098/ea027581701ex4-10_envoy.htm) | S-1 | 333-292260 | 4.10 | February 6, 2026 |
| 4.11 (\*\*) | [Form of Series A-2 Warrant to be issued in this offering](https://www.sec.gov/Archives/edgar/data/1840877/000121390026013098/ea027581701ex4-11_envoy.htm) | S-1 | 333-292260 | 4.11 | February 6, 2026 |
| 4.12 (\*\*) | [Form of Placement Agent Warrant to be issued in this offering](https://www.sec.gov/Archives/edgar/data/1840877/000121390026013098/ea027581701ex4-12_envoy.htm) | S-1 | 333-292260 | 4.12 | February 6, 2026 |
| 5.1 (\*\*) | [Opinion of Fredrikson & Byon, P.A.](https://www.sec.gov/Archives/edgar/data/1840877/000121390026013098/ea027581701ex5-1_envoy.htm) | S-1 | 333-292260 | 5.1 | February 6, 2026 |
| 10.1 | [Amendment to Letter Agreement, dated September 29, 2023, by and among Anzu Special Acquisition Corp I, Anzu SPAC GP I LLC and Anzu's officers and directors.](http://www.sec.gov/Archives/edgar/data/1840877/000101376223002246/ea186352ex10-2_envoy.htm) | 8-K | 001-40133 | 10.2 | October 5, 2023 |
| 10.2 (+) | [Amended and Restated Registration Rights Agreement, dated September 29, 2023, by and among Anzu Special Acquisition Corp I, Anzu SPAC GP I LLC and certain stockholders.](http://www.sec.gov/Archives/edgar/data/1840877/000101376223002246/ea186352ex10-3_envoy.htm) | 8-K | 001-40133 | 10.3 | October 5, 2023 |
| 10.3 (\*) | [Envoy Medical, Inc. Equity Incentive Plan.](http://www.sec.gov/Archives/edgar/data/1840877/000101376223002246/ea186352ex10-22_envoy.htm) | 8-K | 001-40133 | 10.22 | October 5, 2023 |
| 10.4 (\*) | [Envoy Medical, Inc. Employee Stock Purchase Plan.](http://www.sec.gov/Archives/edgar/data/1840877/000101376223002246/ea186352ex10-23_envoy.htm) | 8-K | 001-40133 | 10.23 | October 5, 2023 |
| 10.5 (\*) | [Form of Envoy Medical, Inc. Indemnification Agreement.](http://www.sec.gov/Archives/edgar/data/1840877/000101376223002246/ea186352ex10-21_envoy.htm) | 8-K | 001-40133 | 10.21 | October 5, 2023 |
| 10.6 | [Forward Purchase Agreement, dated as of April 17, 2023.](http://www.sec.gov/Archives/edgar/data/1840877/000110465923046443/tm2312890d1_ex10-4.htm) | 8-K | 001-40133 | 10.4 | April 18, 2023 |
| 10.7 (+) | [Amendment No. 1 to Forward Purchase Agreement, dated as of May 25, 2023.](http://www.sec.gov/Archives/edgar/data/1840877/000110465923077199/anzuu-20230331xex10d27.htm) | S-4/A | 333-271920 | 10.27 | June 30, 2023 |
| 10.8 | [Amendment No. 2 to Forward Purchase Agreement, dated as of September 28, 2023.](http://www.sec.gov/Archives/edgar/data/1840877/000101376223002246/ea186352ex10-24_envoy.htm) | 8-K | 001-40133 | 10.24 | October 5, 2023 |
| 10.9 (\*) | [Employment Agreement, dated October 16, 2023, between Envoy Medical Corporation and Brent T. Lucas.](http://www.sec.gov/Archives/edgar/data/1840877/000101376223005437/ea187058ex10-1_envoy.htm) | 8-K | 001-40133 | 10.1 | October 20, 2023 |
| 10.10 (\*) | [Employment Agreement, dated August 15, 2023, between Envoy Medical Corporation and David R. Wells.](http://www.sec.gov/Archives/edgar/data/1840877/000121390023088310/f10q0923ex10-10_envoy.htm) | 10-Q | 001-40133 | 10.10 | November 17, 2023 |
| 10.11 (\*) | [Letter Agreement, dated February 14, 2024, between Envoy Medical Corporation and Charles R. Brynelsen.](http://www.sec.gov/Archives/edgar/data/1840877/000121390024028894/ea020296601ex10-11_envoy.htm) | 10-K | 001-40133 | 10.11 | April 1, 2024 |
| 10.12 (\*) | [Letter Agreement, dated February 14, 2024, between Envoy Medical Corporation and Susan Kantor.](http://www.sec.gov/Archives/edgar/data/1840877/000121390024028894/ea020296601ex10-12_envoy.htm) | 10-K | 001-40133 | 10.12 | April 1, 2024 |
| 10.13 (\*) | [Letter Agreement, dated February 14, 2024, between Envoy Medical Corporation and Mona Patel.](http://www.sec.gov/Archives/edgar/data/1840877/000121390024028894/ea020296601ex10-13_envoy.htm) | 10-K | 001-40133 | 10.13 | April 1, 2024 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| 10.14 (\*) | [Letter Agreement, dated February 14, 2024, between Envoy Medical Corporation and Janis Smith-Gomez.](http://www.sec.gov/Archives/edgar/data/1840877/000121390024028894/ea020296601ex10-14_envoy.htm) | 10-K | 001-40133 | 10.14 | April 1, 2024 |
| 10.15 (\*) | [Form of Option Award Agreement.](http://www.sec.gov/Archives/edgar/data/1840877/000121390024028894/ea020296601ex10-15_envoy.htm) | 10-K | 001-40133 | 10.15 | April 1, 2024 |
| 10.16 | [Promissory Note, dated February 27, 2024, between Envoy Medical, Inc. and GAT Funding, LLC](http://www.sec.gov/Archives/edgar/data/1840877/000121390024043566/ea020583701ex10-1_envoy.htm) | 10-Q | 001-40133 | 10.1 | May 15, 2024 |
| 10.17 | [Amendment to Forward Stock Purchase Agreement, dated July 29, 2024, between Envoy Medical, Inc. and the Meteroa FPA Parties.](http://www.sec.gov/Archives/edgar/data/1840877/000101376224003336/ea021039602ex10-1_envoy.htm) | 8-K | 001-40133 | 10.1 | August 1, 2024 |
| 10.18 | [Promissory Note, dated August 27, 2024, between Envoy Medical, Inc. and GAT Funding, LLC.](http://www.sec.gov/Archives/edgar/data/1840877/000121390024097861/ea022095601ex10-1_envoy.htm) | 10-Q | 001-40133 | 10.1 | November 14, 2024 |
| 10.19 | [Conversion and Waiver Agreement, dated December 20, 2024, by and between Envoy Medical, Inc. and Anzu SPAC GP I LLC.](http://www.sec.gov/Archives/edgar/data/1840877/000121390024111279/ea022560401ex10-1_envoy.htm) | 8-K | 001-40133 | 10.1 | December 20, 2024 |
| 10.20 | [Amendment No. 1 to Common Stock Purchase Warrant, issued by Envoy Medical, Inc. to the Meteora Parties.](http://www.sec.gov/Archives/edgar/data/1840877/000121390024055739/ea020840901ex10-1_envoy.htm) | 8-K | 001-40133 | 10.1 | June 25, 2024 |
| 10.21 | [Amendment No. 2 to Common Stock Purchase Warrant, issued by Envoy Medical, Inc. to the Meteora Parties.](http://www.sec.gov/Archives/edgar/data/1840877/000121390024111932/ea022575701ex10-1_envoy.htm) | 8-K | 001-40133 | 10.1 | December 23, 2024 |
| 10.22 | [At The Market Offering Agreement dated as of January 17, 2025, between Envoy Medical, Inc and Roth Capital Partners, LLC](http://www.sec.gov/Archives/edgar/data/1840877/000121390025004714/ea022806401ex10-1_envoy.htm) | 8-K | 001-40133 | 10.1 | January 21, 2025 |
| 10.23 | [Building Lease dated as of May 20, 2016, between Envoy Medical Corporation and Taylor Corporation, as amended.](http://www.sec.gov/Archives/edgar/data/1840877/000101376225004299/ea023532001ex10-23_envoy.htm) | 10-K | 001-40133 | 10.23 | March 31, 2025 |
| 10.24 | [Servies Agreement dated as of January 1, 2022, between Envoy Medical Corporation and Taylor Technology Services, Inc.](http://www.sec.gov/Archives/edgar/data/1840877/000101376225004299/ea023532001ex10-24_envoy.htm) | 10-K | 001-40133 | 10.24 | March 31, 2025 |
| 10.25 | [Promissory Note, dated March 6, 2025, between Envoy Medical, Inc. and GAT Funding, LLC.](http://www.sec.gov/Archives/edgar/data/1840877/000121390025038468/ea023963901ex10-2_envoymed.htm) | 10-Q | 001-40133 | 10.2 | May 1, 2025 |
| 10.26 | [Amended and Restated Envoy Medical, Inc. 2023 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1840877/000121390025050758/ea024441801ex10-1_envoy.htm) | 8-K | 001-40133 | 10.1 | June 3, 2025 |
| 10.27 | [Consulting Agreement by and between the Company and Oasis Business Consulting, LLC, dated effective June 23, 2025.](http://www.sec.gov/Archives/edgar/data/1840877/000121390025057481/ea024682601ex10-1_envoy.htm) | 8-K | 001-40133 | 10.1 | June 25, 2025 |
| 10.28 | [Satisfaction of Promissory Notes by and between the Company and GAT Funding, LLC, dated effective August 25, 2025.](http://www.sec.gov/Archives/edgar/data/1840877/000121390025080530/ea025459001ex10-1_envoy.htm) | 8-K | 001-40133 | 10.1 | August 26, 2025 |
| 10.29 | [Amendment to Forward Stock Purchase Agreement, between the Meteora FPA Parties and the Company, dated July 28, 2025.](http://www.sec.gov/Archives/edgar/data/1840877/000121390025068760/ea025064901ex10-1_envoy.htm) | 8-K | 001-40133 | 10.1 | July 29, 2025 |
| 10.30 | [Warrant Extension and Voting Agreement, by and among the Company, GAT Funding, LLC, Taylor Sports Group, Inc., and Glen A. Taylor, dated September 4, 2025.](http://www.sec.gov/Archives/edgar/data/1840877/000121390025086268/ea025665001ex10-1_envoy.htm) | 8-K | 001-40133 | 10.1 | September 9, 2025 |
| 10.31 | [Form of September Purchase Agreement](http://www.sec.gov/Archives/edgar/data/1840877/000121390025090373/ea025837101ex10-1_envoy.htm) | 8-K | 001-40133 | 10.1 | September 23, 2025 |
| 10.32 | [Form of October Purchase Agreement](http://www.sec.gov/Archives/edgar/data/1840877/000121390025097600/ea026075301ex10-1_envoy.htm) | 8-K | 001-40133 | 10.1 | October 9, 2025 |
| 10.33(\*\*) | [Form of Securities Purchase Agreement to be entered into in connection with this offering](http://www.sec.gov/Archives/edgar/data/1840877/000121390026013098/ea027581701ex10-33_envoy.htm) | S-1 | 333-292260 | 10.33 | February 6, 2026 |
| 10.34(#) | [Engagement Letter, dated September 17, 2025, by and between Envoy Medical, Inc. and H.C. Wainwright & Co., LLC, as amended on December 17, 2025 and February 9, 2026.](ea027620701ex10-34_envoy.htm) |  |  |  |  |
| 21.1 | [List of Subsidiaries.](http://www.sec.gov/Archives/edgar/data/1840877/000101376225004299/ea023532001ex21-1_envoy.htm) | 10-K | 001-40133 | 21.1 | March 31, 2025 |
| 23.1(\*\*) | [Consent of Grant Thornton LLP.](https://www.sec.gov/Archives/edgar/data/1840877/000121390026013098/ea027581701ex23-1_envoy.htm) | S-1 | 333-292260 | 23.1 | February 6, 2026 |
| 23.2(\*\*) | [Consent of Fredrikson & Byron, P.A. (included as part of Exhibit 5.1).](https://www.sec.gov/Archives/edgar/data/1840877/000121390026013098/ea027581701ex5-1_envoy.htm) | S-1 | 333-292260 | 5.1 | February 6, 2026 |
| 24.1(\*\*) | [Power of Attorney (included on signature page to this Registration Statement).](https://www.sec.gov/ix?doc=/Archives/edgar/data/1840877/000121390025123367/ea0268759-s1_envoy.htm#s_001) | S-1 | 333-292260 |  | February 6, 2026 |
| 107(\*\*) | [Filing Fee Table](http://www.sec.gov/Archives/edgar/data/1840877/000121390025123367/ea026875901ex-fee_envoy.htm) | S-1 | 333-292260 | 107 | February 6, 2026 |

---

(\*) Indicates a management contract or compensatory plan. <br>(\*\*) Previously filed

(#) Filed herewith.

---

| | |
|:---|:---|
| (+) | Certain schedules and exhibits to this Exhibit have been omitted pursuant to Item 601(a)(5) or Item 601(b)(10)(iv), as applicable, of Regulation S-K The Registrant agrees to furnish supplemental copies of all omitted exhibits and schedules to the Securities and Exchange Commission upon its request. |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of White Bear Lake, State of Minnesota on February 9, 2026.

---

| | |
|:---|:---|
| **ENVOY MEDICAL, INC.** | **ENVOY MEDICAL, INC.** |
| /s/ Brent T. Lucas | /s/ Brent T. Lucas |
| Name: | Brent T. Lucas |
| Title: | Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Brent T. Lucas | Chief Executive Officer and Director | February 9, 2026 |
| Brent T. Lucas | (Principal Executive Officer) |  |
| \* | Interim Chief Financial Officer | February 9, 2026 |
| Robert Potashnick | (Principal Financial and Accounting Officer) |  |
| \* | Director | February 9, 2026 |
| Charles R. Brynelsen |  |  |
| \* | Director | February 9, 2026 |
| Michael Crowe |  |  |
| \* | Director | February 9, 2026 |
| Mona Patel |  |  |
| \* | Director | February 9, 2026 |
| Janis Smith-Gomez |  |  |
| \* | Director | February 9, 2026 |
| Susan J. Kantor |  |  |

---

---

| | | |
|:---|:---|:---|
| \*By: | /s/ Brent T. Lucas | Date: February 9, 2026 |
| Name: | Brent T. Lucas |  |
| Title: | Attorney-in-Fact |  |

---

## Exhibit 10.34

**Exhibit 10.34**

![](ex10-34_001.jpg)

**<u>Execution Version</u>**

September 17, 2025

<u>STRICTLY CONFIDENTIAL</u>

Envoy Medical, Inc.

4875 White Bear Parkway

White Bear Lake, MN 55110

Attn: Brent T. Lucas, Chief Executive Officer

Dear Mr. Lucas:

This letter agreement (this "<u>Agreement</u>") constitutes the agreement between Envoy Medical, Inc. (the "<u>Company</u>") and H.C. Wainwright & Co., LLC ("<u>Wainwright</u>"), that Wainwright shall serve as the exclusive underwriter, agent or advisor in any offering (each, an "<u>Offering</u>") of securities of the Company (the "<u>Securities</u>") during the Term (as hereinafter defined) of this Agreement, including, but not limited to, a so-called at-the-market facility and each sale made thereunder ("<u>ATM</u>"). The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright. Nothing herein implies that Wainwright would have the power or authority to bind the Company, and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright's assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright in connection with an Offering. The Company expressly acknowledges and agrees that Wainwright's involvement in an Offering is strictly on a reasonable best efforts basis and that the consummation of an Offering will be subject to, among other things, market conditions. The execution of this Agreement does not constitute a commitment by Wainwright to purchase the Securities and does not ensure a successful Offering of the Securities or the success of Wainwright with respect to securing any other financing on behalf of the Company. Wainwright may retain other underwriters, brokers, dealers or agents on its behalf in connection with an Offering. Wainwright acknowledges that Company has expressed its desire to raise at least $4.0 million in the aggregate pursuant to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. <u>Compensation; Reimbursement</u>. The Company shall compensate Wainwright as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. *Cash Fee*. The Company shall pay Wainwright a cash fee, or as to an underwritten Offering an underwriter
discount, equal to 7.5% of the aggregate gross proceeds raised at each closing of each Offering (each, a " <u>Closing</u> ");
provided, however, that the cash fee for an ATM shall equal 3.0% of the aggregate gross proceeds raised in each sale pursuant to an ATM.
In addition, upon the exercise for cash of any privately-placed, unregistered warrants issued to investors in an Offering, the Company
shall pay Wainwright, within five (5) business days of the Company's receipt of the exercise price, (i) a cash fee of 7.5% of the
aggregate gross exercise price paid in cash with respect thereto; and (ii) a management fee of 1.0% of the aggregate gross exercise price
paid in cash with respect thereto.

430 Park Avenue \| New York, New York 10022 \| 212.356.0500 \| www.hcwco.com

Member: FINRA/SIPC

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. *Warrant Coverage*. The Company shall issue to Wainwright or its designees at each Closing warrants
(the " <u>Wainwright Warrants</u> ") to purchase that number of shares of common stock of the Company equal to 7.5% of the aggregate
number of shares of common stock (or pre-funded warrants in lieu thereof) placed in each Offering (and if an Offering includes a "greenshoe"
or "additional investment" component, such number of shares of common stock underlying such "greenshoe" or "additional
investment" component, with the Wainwright Warrants issuable upon the exercise of such component); provided, however, that no warrants
will be issued to Wainwright in connection with an ATM. If the Securities included in an Offering are convertible, the Wainwright Warrants
shall be determined by dividing the gross proceeds raised in such Offering by the Offering Price (as defined hereunder). The Wainwright
Warrants shall be in a customary form reasonably acceptable to Wainwright, have a term of five (5) years and an exercise price equal to
125% of the offering price per share (or unit, if applicable) in the applicable Offering and if such offering price is not available,
the market price of the common stock on the date an Offering is commenced (such price, the " <u>Offering Price</u> "). If warrants
are issued to investors in an Offering, the Wainwright Warrants shall have the same terms as the warrants issued to investors in the applicable
Offering, except that such Wainwright Warrants shall have an exercise price equal to 125% of the Offering Price. In addition, upon the
exercise for cash of any privately-placed, unregistered warrants issued to investors in an Offering, the Company shall issue to Wainwright
(or its designees), within five (5) business days of the Company's receipt of the exercise price, the Wainwright Warrants to purchase
that number of shares of common stock of the Company equal to 7.5% of the aggregate number of such shares of common stock underlying such
warrants that have been so exercised and such Wainwright Warrants will be in the same form and terms as the Wainwright Warrants originally
issued in the applicable Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. *Expense Allowance*. Out of the proceeds of each Closing, the Company also agrees to pay Wainwright
(a) a management fee equal to 1.0% of the gross proceeds raised in each Offering; (b) $35,000 for non-accountable expenses; (c) up to
$50,000 for fees and expenses of legal counsel and other out-of-pocket expenses (to be increased to $100,000 in case a public Offering
is contemplated or consummated); plus the additional amount payable by the Company pursuant to Paragraph D.4 hereunder and, if applicable,
the costs associated with the use of a third-party electronic road show service (such as NetRoadshow); provided, however, that such amounts
in no way limit or impair the indemnification and contribution provisions of this Agreement.

Notwithstanding anything to the contrary included in the preceding paragraph, in connection with an ATM, the Company shall pay Wainwright up to $75,000 for fees and expenses of its legal counsel in addition to any other out-of-pocket expenses that will be incurred by the Company and Wainwright in connection with the set-up, execution, performance and maintenance of the ATM.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. *Tail*. Wainwright shall be entitled to compensation under clauses (1) and (2) hereunder, calculated
in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any
kind (" <u>Tail Financing</u> ") to the extent that any capital or funds in such Tail Financing is provided to the Company directly
or indirectly by investors whom Wainwright had contacted during the Term or introduced to the Company during the Term, if such Tail Financing
is consummated at any time within the 12-month period following the expiration or termination of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. *Right of First Refusal*. If, from the date hereof until the 12-month anniversary following consummation
of each Offering (subject to FINRA Rule 5110(g)(6)(A)), the Company or any of its subsidiaries (a) decides to dispose of or acquire business
units or acquire any of its outstanding securities or make any exchange or tender offer or enter into a merger, consolidation or other
business combination or any recapitalization, reorganization, restructuring or other similar transaction, including, without limitation,
an extraordinary dividend or distributions or a spin-off or split-off, Wainwright (or any affiliate designated by Wainwright) shall have
the right to act as the Company's exclusive financial advisor for any such transaction; or (b) decides to finance or refinance any
indebtedness, Wainwright (or any affiliate designated by Wainwright) shall have the right to act as sole book-runner, sole manager, sole
placement agent or sole agent with respect to such financing or refinancing; or (c) decides to raise funds by means of a public offering
(including ATMs) or a private placement or any other capital-raising financing of equity, equity-linked or debt securities, Wainwright
(or any affiliate designated by Wainwright) shall have the right to act as sole book-running manager, sole underwriter or sole placement
agent for such financing. If Wainwright or one of its affiliates decides to accept any such engagement, the agreement governing such engagement
will contain, among other things, provisions for customary fees for transactions of similar size and nature and the provisions of this
Agreement, including indemnification, which are appropriate to such a transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. <u>Term and Termination of Engagement; Exclusivity</u>. The term of Wainwright's exclusive engagement will begin on the date hereof and end ninety (90) days thereafter (the "<u>Initial Term</u>"); provided, however, that if an Offering is consummated within the Initial Term, the term of this Agreement shall be extended by an additional ninety (90) day period (the "<u>Extension Term</u>," and together with the Initial Term, the "<u>Term</u>"). For clarity, the term "Term" shall mean the Initial Term if there is no Extension Term. Notwithstanding anything to the contrary contained herein, the Company agrees that the provisions relating to the payment of fees, reimbursement of expenses, right of first refusal, tail, indemnification and contribution, confidentiality, conflicts, independent contractor and waiver of the right to trial by jury will survive any termination or expiration of this Agreement. Notwithstanding anything to the contrary contained herein, the Company has the right to terminate the Agreement for cause in compliance with FINRA Rule 5110(g)(5)(B)(i). The exercise of such right of termination for cause eliminates the Company's obligations with respect to the provisions relating to the tail fees and right of first refusal. Notwithstanding anything to the contrary contained in this Agreement, in the event that an Offering pursuant to this Agreement shall not be carried out for any reason whatsoever during the Term, the Company shall be obligated to pay to Wainwright its actual and accountable out-of-pocket expenses related to an Offering (including the fees and disbursements of Wainwright's legal counsel) and, if applicable, for electronic road show service used in connection with an Offering. During Wainwright's engagement hereunder: (i) the Company will not, and will not permit its representatives to, other than in coordination with Wainwright, contact or solicit institutions, corporations or other entities or individuals as potential purchasers of the Securities or investment banks in connection with an Offering and (ii) the Company will not pursue any financing transaction which would be in lieu of an Offering. Furthermore, the Company agrees that during Wainwright's engagement hereunder, all inquiries from prospective investors will be referred to Wainwright. Additionally, except as set forth hereunder, the Company represents, warrants and covenants that no brokerage or finder's fees or commissions are or will be payable by the Company or any subsidiary of the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other third-party with respect to any Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. <u>Information; Reliance</u>. The Company shall use commercially reasonable efforts furnish, or cause to be furnished, to Wainwright all information requested by Wainwright for the purpose of rendering services hereunder and conducting due diligence (all such information being the "<u>Information</u>"). In addition, the Company agrees to make available to Wainwright upon request from time to time the officers, directors, accountants, counsel and other advisors of the Company. The Company recognizes and confirms that Wainwright (a) will use and rely on the Information, including any documents provided to investors in each Offering (the "<u>Offering Documents</u>") which shall include any Purchase Agreement (as defined hereunder), and on information available from generally recognized public sources in performing the services contemplated by this Agreement without having independently verified the same; (b) does not assume responsibility for the accuracy or completeness of the Offering Documents or the Information and such other information; and (c) will not make an appraisal of any of the assets or liabilities of the Company. Upon reasonable request, the Company will meet with Wainwright or its representatives to discuss all information relevant for disclosure in the Offering Documents and will cooperate in any investigation undertaken by Wainwright thereof, including any document included or incorporated by reference therein. At each Offering, at the request of Wainwright, the Company shall deliver such legal letters (including, without limitation, negative assurance letters), opinions, comfort letters, officers' and secretary certificates and good standing certificates, all in form and substance satisfactory to Wainwright and its counsel as is customary for such Offering. Wainwright shall be a third party beneficiary of any representations, warranties, covenants, closing conditions and closing deliverables made by the Company in any Offering Documents, including representations, warranties, covenants, closing conditions and closing deliverables made to any investor in an Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. <u>Related Agreements</u>. At each Offering, the Company shall enter into the following additional agreements, as applicable:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. *Underwritten Offering*. If an Offering is an underwritten Offering, the Company and Wainwright shall
enter into a customary underwriting agreement in form and substance satisfactory to Wainwright and its counsel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. *Best Efforts Offering*. If an Offering is on a best efforts basis, the sale of Securities to the
investors in the Offering will be evidenced by a purchase agreement (" <u>Purchase Agreement</u> ") between the Company and
such investors in a form reasonably satisfactory to the Company and Wainwright. Wainwright shall be a third party beneficiary with respect
to the representations, warranties, covenants, closing conditions and closing deliverables included in the Purchase Agreement. Prior to
the signing of any Purchase Agreement, officers of the Company with responsibility for financial affairs will be available to answer inquiries
from prospective investors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. *ATM Offering*. If an Offering is an ATM, the Company and Wainwright shall enter into a customary
at-the-market sales agreement in form and substance satisfactory to Wainwright and its counsel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. *Escrow, Settlement and Closing*. If each Offering is not settled via delivery versus payment (" <u>DVP</u> "),
the Company and Wainwright shall enter into an escrow agreement with a third party escrow agent pursuant to which Wainwright's compensation
and expenses shall be paid from the gross proceeds of the Securities sold. If the Offering is settled in whole or in part via DVP, Wainwright
shall arrange for its clearing agent to provide the funds to facilitate such settlement; provided, however, if the clearing firm provides
the funds in a best efforts offering and subsequent to such delivery an investor fails to provide the necessary funds to the clearing
agent for such purchase of Securities, Wainwright shall instruct the clearing agent to promptly return any such Securities to the Company
and the Company shall promptly return such investor's purchase price to the clearing agent. The Company shall pay Wainwright closing
costs, which shall also include the reimbursement of the documented, out-of-pocket cost of the escrow agent or clearing agent, as applicable,
which closing costs shall not exceed $15,950.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. *FINRA Amendments*. Notwithstanding anything herein to the contrary, in the event that Wainwright
determines that any of the terms provided for hereunder shall not comply with a FINRA rule, including but not limited to FINRA Rule 5110,
then the Company shall agree to amend this Agreement (or include such revisions in the final underwriting agreement) in writing upon the
request of Wainwright to comply with any such rules; provided that any such amendments shall not provide for terms that are less favorable
to the Company than are reflected in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;E. <u>Confidentiality</u>. In the event of the consummation or public announcement of any Offering, Wainwright shall have the right to disclose its participation in such Offering, including, without limitation, the Offering at its cost of "tombstone" advertisements in financial and other newspapers and journals.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;F. <u>Indemnity</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. In connection with the Company's engagement of Wainwright hereunder, the Company hereby agrees to
indemnify and hold harmless Wainwright and its affiliates, and the respective controlling persons, directors, officers, members, shareholders,
agents and employees of any of the foregoing (collectively the " <u>Indemnified Persons</u> "), from and against any and all
claims, actions, suits, proceedings (including those of shareholders), damages, liabilities and expenses incurred by any of them (including
the reasonable fees and expenses of counsel), as incurred, whether or not the Company is a party thereto (collectively a " <u>Claim</u> "),
that are (A) related to or arise out of (i) any actions taken or omitted to be taken (including any untrue statements made or any statements
omitted to be made) by the Company, or (ii) any actions taken or omitted to be taken by any Indemnified Person in connection with the
Company's engagement of Wainwright, or (B) otherwise relate to or arise out of Wainwright's activities on the Company's
behalf under Wainwright's engagement, and the Company shall reimburse any Indemnified Person for all expenses (including the reasonable
fees and expenses of counsel) as incurred by such Indemnified Person in connection with investigating, preparing or defending any such
claim, action, suit or proceeding, whether or not in connection with pending or threatened litigation in which any Indemnified Person
is a party. The Company will not, however, be responsible for any Claim that is finally judicially determined to have resulted from the
gross negligence or willful misconduct of any such Indemnified Person for such Claim. The Company further agrees that no Indemnified Person
shall have any liability to the Company for or in connection with the Company's engagement of Wainwright except for any Claim incurred
by the Company as a result of such Indemnified Person's gross negligence or willful misconduct.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The Company further agrees that it will not, without the prior written consent of Wainwright, settle,
compromise or consent to the entry of any judgment in any pending or threatened Claim in respect of which indemnification may be sought
hereunder (whether or not any Indemnified Person is an actual or potential party to such Claim), unless such settlement, compromise or
consent includes an unconditional, irrevocable release of each Indemnified Person from any and all liability arising out of such Claim.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Promptly upon receipt by an Indemnified Person of notice of any complaint or the assertion or institution
of any Claim with respect to which indemnification is being sought hereunder, such Indemnified Person shall notify the Company in writing
of such complaint or of such assertion or institution but failure to so notify the Company shall not relieve the Company from any obligation
it may have hereunder, except and only to the extent such failure results in the forfeiture by the Company of substantial rights and defenses.
If the Company is requested by such Indemnified Person, the Company will assume the defense of such Claim, including the employment of
counsel for such Indemnified Person and the payment of the fees and expenses of such counsel, provided, however, that such counsel shall
be satisfactory to the Indemnified Person and provided further that if the legal counsel to such Indemnified Person reasonably determines
that the use of counsel chosen by the Company to represent such Indemnified Person would present such counsel with a conflict of interest
or if the defendant in, or target of, any such Claim, includes an Indemnified Person and the Company, and legal counsel to such Indemnified
Person reasonably concludes that there may be legal defenses available to it or other Indemnified Persons different from or in addition
to those available to the Company, such Indemnified Person will employ its own separate counsel (including local counsel, if necessary)
to represent or defend him, her or it in any such Claim and the Company shall pay the reasonable fees and expenses of such counsel. If
such Indemnified Person does not request that the Company assume the defense of such Claim, such Indemnified Person will employ its own
separate counsel (including local counsel, if necessary) to represent or defend him, her or it in any such Claim and the Company shall
pay the reasonable fees and expenses of such counsel. Notwithstanding anything herein to the contrary, if the Company fails timely or
diligently to defend, contest, or otherwise protect against any Claim, the relevant Indemnified Person shall have the right, but not the
obligation, to defend, contest, compromise, settle, assert crossclaims, or counterclaims or otherwise protect against the same, and shall
be fully indemnified by the Company therefor, including without limitation, for the reasonable fees and expenses of its counsel and all
amounts paid as a result of such Claim or the compromise or settlement thereof. In addition, with respect to any Claim in which the Company
assumes the defense, the Indemnified Person shall have the right to participate in such Claim and to retain his, her or its own counsel
therefor at his, her or its own expense.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The Company agrees that if any indemnity sought by an Indemnified Person hereunder is held by a court
to be unavailable for any reason then (whether or not Wainwright is the Indemnified Person), the Company and Wainwright shall contribute
to the Claim for which such indemnity is held unavailable in such proportion as is appropriate to reflect the relative benefits to the
Company, on the one hand, and Wainwright on the other, in connection with Wainwright's engagement referred to above, subject to
the limitation that in no event shall the amount of Wainwright's contribution to such Claim exceed the amount of fees actually received
by Wainwright from the Company pursuant to Wainwright's engagement. The Company hereby agrees that the relative benefits to the
Company, on the one hand, and Wainwright on the other, with respect to Wainwright's engagement shall be deemed to be in the same
proportion as (a) the total value paid or proposed to be paid or received by the Company pursuant to the applicable Offering (whether
or not consummated) for which Wainwright is engaged to render services bears to (b) the fee paid or proposed to be paid to Wainwright
in connection with such engagement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The Company's indemnity, reimbursement and contribution obligations under this Agreement (a) shall
be in addition to, and shall in no way limit or otherwise adversely affect any rights that any Indemnified Person may have at law or at
equity and (b) shall be effective whether or not the Company is at fault in any way.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;G. <u>Limitation of Engagement to the Company</u>. The Company acknowledges that Wainwright has been retained only by the Company, that Wainwright is providing services hereunder as an independent contractor (and not in any fiduciary or agency capacity) and that the Company's engagement of Wainwright is not deemed to be on behalf of, and is not intended to confer rights upon, any shareholder, owner or partner of the Company or any other person not a party hereto as against Wainwright or any of its affiliates, or any of its or their respective officers, directors, controlling persons (within the meaning of Section 15 of the Securities Act of 1933, as amended (the "<u>Securities Act</u>") or Section 20 of the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>")), employees or agents. Unless otherwise expressly agreed in writing by Wainwright, no one other than the Company is authorized to rely upon this Agreement or any other statements or conduct of Wainwright, and no one other than the Company is intended to be a beneficiary of this Agreement. The Company acknowledges that any recommendation or advice, written or oral, given by Wainwright to the Company in connection with Wainwright's engagement is intended solely for the benefit and use of the Company's management and directors in considering a possible Offering, and any such recommendation or advice is not on behalf of, and shall not confer any rights or remedies upon, any other person or be used or relied upon for any other purpose. Wainwright shall not have the authority to make any commitment binding on the Company. The Company, in its sole discretion, shall have the right to reject any investor introduced to it by Wainwright.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;H. <u>Limitation of Wainwright's Liability to the Company</u>. Wainwright and the Company further agree that neither Wainwright nor any of its affiliates or any of its or their respective officers, directors, controlling persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act), employees or agents shall have any liability to the Company, its security holders or creditors, or any person asserting claims on behalf of or in the right of the Company (whether direct or indirect, in contract, tort, for an act of negligence or otherwise) for any losses, fees, damages, liabilities, costs, expenses or equitable relief arising out of or relating to this Agreement or the services rendered hereunder, except for losses, fees, damages, liabilities, costs or expenses that arise out of or are based on any action of or failure to act by Wainwright and that are finally judicially determined to have resulted solely from the gross negligence or willful misconduct of Wainwright.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I. <u>Governing Law</u>. This Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be fully performed therein. Any disputes that arise under this Agreement, even after the termination of this Agreement, will be heard only in the state or federal courts located in the City of New York, State of New York. The parties hereto expressly agree to submit themselves to the jurisdiction of the foregoing courts in the City of New York, State of New York. The parties hereto expressly waive any rights they may have to contest the jurisdiction, venue or authority of any court sitting in the City and State of New York. In the event Wainwright or any Indemnified Person is successful in any action, or suit against the Company, arising out of or relating to this Agreement, the final judgment or award entered shall be entitled to have and recover from the Company the costs and expenses incurred in connection therewith, including its reasonable attorneys' fees. Any rights to trial by jury with respect to any such action, proceeding or suit are hereby waived by Wainwright and the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;J. <u>Notices</u>. All notices hereunder will be in writing and sent by certified mail, hand delivery, overnight delivery or e-mail, if sent to Wainwright, at the address set forth on the first page hereof, e-mail: notices@hcwco.com, Attention: Head of Investment Banking, and if sent to the Company, to the address set forth on the first page hereof, e-mail: Brent Lucas, Attention: Chief Executive Officer, with a copy, which shall not constitute notice, to the Company's legal counsel at Fredrikson & Byron, PA, 60 South Sixth Street, Suite 1500, Minneapolis, Minnesota 55402, Attention: Andrew Nick, email: anick@fredlaw.com. Notices sent by certified mail shall be deemed received five days thereafter, notices sent by hand delivery or overnight delivery shall be deemed received on the date of the relevant written record of receipt, notices sent by e-mail shall be deemed received as of the date and time they were sent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;K. <u>Conflicts</u>. The Company acknowledges that Wainwright and its affiliates may have and may continue to have investment banking and other relationships with parties other than the Company pursuant to which Wainwright may acquire information of interest to the Company. Wainwright shall have no obligation to disclose such information to the Company or to use such information in connection with any contemplated transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;L. <u>Anti-Money Laundering</u>. To help the United States government fight the funding of terrorism and money laundering, the federal laws of the United States require all financial institutions to obtain, verify and record information that identifies each person with whom they do business. This means Wainwright must ask the Company for certain identifying information, including a government-issued identification number (e.g., a U.S. taxpayer identification number) and such other information or documents that Wainwright considers appropriate to verify the Company's identity, such as certified articles of incorporation, a government-issued business license, a partnership agreement or a trust instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;M. <u>Miscellaneous</u>. The Company represents and warrants that it has all requisite power and authority to enter into and carry out the terms and provisions of this Agreement and the execution, delivery and performance of this Agreement does not breach or conflict with any agreement, document or instrument to which it is a party or bound. Furthermore, the Company represents and warrants that no consent, permit, waiver, approval or authorization of any third party in connection with the execution, delivery and performance by the Company of this Agreement or an Offering, is required or has not been obtained. This Agreement shall not be modified or amended except in writing signed by Wainwright and the Company. This Agreement shall be binding upon and inure to the benefit of both Wainwright and the Company and their respective assigns, successors, and legal representatives. This Agreement constitutes the entire agreement of Wainwright and the Company with respect to the subject matter hereof and supersedes any prior agreements with respect to the subject matter hereof. If any provision of this Agreement is determined to be invalid or unenforceable in any respect, such determination will not affect such provision in any other respect, and the remainder of the Agreement shall remain in full force and effect. This Agreement may be executed in counterparts (including electronic counterparts), each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Signatures to this Agreement transmitted by electronic mail in "portable document format" (.pdf) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature. The undersigned hereby consents to receipt of this Agreement in electronic form and understands and agrees that this Agreement may be signed electronically. In the event that any signature is delivered by electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or otherwise by electronic transmission evidencing an intent to sign this Agreement, such electronic mail or other electronic transmission shall create a valid and binding obligation of the undersigned with the same force and effect as if such signature were an original. Execution and delivery of this Agreement by electronic mail or other electronic transmission is legal, valid and binding for all purposes.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

In acknowledgment that the foregoing correctly sets forth the understanding reached by Wainwright and the Company, please sign in the space provided below, whereupon this letter shall constitute a binding Agreement as of the date indicated above.

---

| | | |
|:---|:---|:---|
| Very truly yours, | Very truly yours, | Very truly yours, |
| **H.C. WAINWRIGHT & CO., LLC** | **H.C. WAINWRIGHT & CO., LLC** | **H.C. WAINWRIGHT & CO., LLC** |
| By: | /s/ Edward D. Silvera | /s/ Edward D. Silvera |
|  | Name: | Edward D. Silvera |
|  | Title: | Chief Operating Officer |
|  | Date: | 9/17/2025 |

---

---

| | | |
|:---|:---|:---|
| Accepted and Agreed: | Accepted and Agreed: | Accepted and Agreed: |
| **Envoy Medical, Inc.** | **Envoy Medical, Inc.** | **Envoy Medical, Inc.** |
| By: | /s/ Brent Lucas | /s/ Brent Lucas |
|  | Name: | Brent Lucas |
|  | Title: | Chief Executive Officer |

---

![](ex10-34_001.jpg)

**<u>Execution Version</u>**

December 17, 2025

<u>STRICTLY CONFIDENTIAL</u>

Envoy Medical, Inc.

4875 White Bear Parkway

White Bear Lake, MN 55110

Attn: Brent T. Lucas, Chief Executive Officer

Dear Mr. Lucas:

Reference is made to the engagement agreement (the "<u>Engagement Agreement</u>"), dated September 17, 2025, by and between Envoy Medical, Inc. (the "<u>Company</u>") and H.C. Wainwright & Co., LLC ("Wainwright"). Defined terms used herein but not defined herein shall have the meanings given to such terms in the Engagement Agreement.

The parties hereby agree to amend the Engagement Agreement (this "<u>Amendment</u>"), as evidenced by their signatures below, under the terms set forth herein as follows:

The parties acknowledge and agree that the Term of the Engagement Agreement shall be extended to and end on December 31, 2026, without any further extension of the Term pursuant to the terms of the Engagement Agreement absent mutual written agreement of the parties.

Additionally, Paragraph A.5 of the Engagement Agreement shall be deleted in its entirety and all references to "right of first refusal" included in the Engagement Agreement shall be deleted in their entirety.

Solely as it pertains to the registered Offering of the Company's equity securities contemplated by the Registration Statement on Form S-1 to be publicly filed on or about the date hereof:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The final sentence of the introductory paragraph is deleted and replaced with "Wainwright acknowledges
that Company has expressed its desire to raise at least $30.0 million in the aggregate pursuant to this Agreement, subject to market conditions
and investor demand."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The cash fee specified in Paragraph A.1 of the Engagement Agreement shall be reduced from "7.5%"
to 7.0%;"

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The warrant coverage specified in Paragraph A.2 of the Engagement Agreement shall be reduced from "7.5%"
to 7.0%;" and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) No payments shall be made to Wainwright pursuant to clauses (a) and (b) of Paragraph A.3 and clearing
fees pursuant to Paragraph D.3 of the Engagement Agreement.

Except as expressly set forth above, all of the terms and conditions of the Engagement Agreement shall continue in full force and effect after the execution of this Amendment and shall not be in any way changed, modified or superseded except as set forth herein. Notwithstanding anything to the contrary contained herein, this Amendment shall be subject to the provisions regarding governing law and miscellaneous provisions set forth in Paragraphs I and M of the Engagement Agreement, and such provisions are incorporated herein by this reference, *mutatis mutandis*.

[*Remainder of page intentionally left blank*]

In acknowledgment that the foregoing correctly sets forth the understanding reached by Wainwright and the Company, please sign in the space provided below, whereupon this Amendment shall constitute a binding agreement as of the date indicated above.

---

| | | |
|:---|:---|:---|
| **H.C. WAINWRIGHT & CO., LLC** | **H.C. WAINWRIGHT & CO., LLC** | **H.C. WAINWRIGHT & CO., LLC** |
| By: | /s/ Edward D. Silvera | /s/ Edward D. Silvera |
|  | Name: | Edward D. Silvera |
|  | Title: | Chief Operating Officer |
|  | Date: | 12/17/2025 |

---

---

| | | |
|:---|:---|:---|
| Accepted and Agreed: | Accepted and Agreed: | Accepted and Agreed: |
| **Envoy Medical, Inc.** | **Envoy Medical, Inc.** | **Envoy Medical, Inc.** |
| By: | /s/ Brent Lucas | /s/ Brent Lucas |
|  | Name: | Brent Lucas |
|  | Title: | Chief Executive Officer |

---

![](ex10-34_001.jpg)

**<u>Execution Version</u>**

February 9, 2026

<u>STRICTLY CONFIDENTIAL</u>

Envoy Medical, Inc.

4875 White Bear Parkway

White Bear Lake, MN 55110

Attn: Brent T. Lucas, Chief Executive Officer

Dear Mr. Lucas:

Reference is made to the engagement agreement by and between Envoy Medical, Inc. (the "Company") and H.C. Wainwright & Co., LLC ("Wainwright"), dated September 17, 2025 as amended on December 17, 2025 (the "Engagement Agreement"). Defined terms used herein but not defined herein shall have the meanings given to such terms in the Engagement Agreement.

The parties hereby agree to amend the Engagement Agreement (this "<u>Amendment</u>"), as evidenced by their signatures below, under the terms set forth herein as follows:

Solely as it pertains to the registered Offering of the Company's equity securities contemplated by the Registration Statement on Form S-1 (File No. 333-292260):

(v) No payments shall be made to Wainwright pursuant to clause (c) of Paragraph A.3 of the Engagement Agreement.

Except as expressly set forth above, all of the terms and conditions of the Engagement Agreement shall continue in full force and effect after the execution of this Amendment and shall not be in any way changed, modified or superseded except as set forth herein. Notwithstanding anything to the contrary contained herein, this Amendment shall be subject to the provisions regarding governing law and miscellaneous provisions set forth in Paragraphs I and M of the Engagement Agreement, and such provisions are incorporated herein by this reference, *mutatis mutandis*.

[*Remainder of page intentionally left blank*]

In acknowledgment that the foregoing correctly sets forth the understanding reached by Wainwright and the Company, please sign in the space provided below, whereupon this Amendment shall constitute a binding agreement as of the date indicated above.

---

| | | |
|:---|:---|:---|
| **H.C. WAINWRIGHT & CO., LLC** | **H.C. WAINWRIGHT & CO., LLC** | **H.C. WAINWRIGHT & CO., LLC** |
| By: | /s/ Edward D. Silvera | /s/ Edward D. Silvera |
|  | Name: | Edward D. Silvera |
|  | Title: | Co-Chief Executive Officer |
|  | Date: | 2/9/2026 |

---

---

| | | |
|:---|:---|:---|
| Accepted and Agreed: | Accepted and Agreed: | Accepted and Agreed: |
| **Envoy Medical, Inc.** | **Envoy Medical, Inc.** | **Envoy Medical, Inc.** |
| By: | /s/ Brent Lucas | /s/ Brent Lucas |
|  | Name: | Brent Lucas |
|  | Title: | Chief Executive Officer |

---